Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients

Trial of Miltuximab in Prostate, Other Cancers Gets Nod to Enroll Additional Patients
The first-in-human clinical trial assessing the safety and tolerability of Miltuximab (MIL-38) — a radiolabeled antibody designed to image prostate, bladder, and pancreatic cancer — is proceeding to its second part, according to Minomic International. Miltuximab is a chimeric version of Minomic’s MIL-38 antibody, linked to the radioactive isotope Gallium-67. A chimeric antibody is one that includes human

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *